TiGenix NV’s Dec. 14 initial public offering was the first biopharmaceutical IPO this month and the 30th for the year, but while 2016 has seen half as many IPOs as 2015, the new crop of publicly traded therapeutics companies are providing much better yields than their 62 peers who launched offerings last year.
TiGenix grossed $42.6m from the sale of 2.75m American depository shares (ADSs), representing 55m ordinary shares, at $15.50 per ADS,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
